ESOLOK Tablet

In those patients who have known hypersensitivity to any component of the formulation.

Headache, abdominal pain, diarrhoea, flatulence, nausea or vomiting etc.

Esomeprazole potentially can increase the concentration of diazepam in blood by decreasing the elimination of diazepam i the liver. The absorption of certain drugs may be affected by stomach acidity. Therefore Esomeprazole and other PPIs that reduce stomach acid also reduce the absorption and concentration of ketoconazole and increase the absorption and concentration of digoxin in blood. This may lead to reduced effectiveness of ketoconazole or increased digoxin toxicity respectively.

Pregnancy

There are no adequate and well-controlled studies with Esomeprazole in pregnant women. This drug may be used during pregnancy (as it is Pregnancy Category B) only if clearly needed.

Lactation

The excretion of Esomeprazole in human breast milk has not been studied. As esomeprazole is likely to be excreted in human breast milk, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Exclude the possibility of malignancy when gastric ulcer is suspected and before treatment for dyspepsia. When using in combination with antibiotic. Refer to the prescribing information of the respective antibiotics. For patient with severe liver impairment, a dose of 20mg of Esomeprazole should not be exceeded

Esolok is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+-ATPase in the gastric parietal cell. By acting specifically on the proton pump, Esolok blocks the final step in acid production, thus reducing gastric acidity.